Novel phenolic compounds extracted from brown seaweeds that inhibit growth and photosynthesis in herbicide-resistant blackgrass, offering a sustainable alternative to synthetic herbicides while improving soil quality and carbon storage.
This research explores the use of phenolic and phenolic-like compounds extracted from brown seaweeds as natural bioactives for crop protection. The focus is on combating herbicide-resistant blackgrass (Alopecurus myosuroides), a major weed that significantly reduces crop yields and is increasingly difficult to control with conventional synthetic herbicides. Seaweed-based treatments offer a sustainable, multifaceted solution: they target resistant pests while concurrently improving soil quality and carbon storage. This approach addresses the urgent need to reduce dependence on synthetic chemical inputs in agriculture.
Key features:
Applications include:
The technology is at an early-to-mid stage of development. Preliminary proof-of-concept data has been generated, demonstrating that brown seaweed extracts are active against herbicide-resistant blackgrass and significantly affect both germination and photophysiology. Future work will optimise extraction protocols, investigate longer-term growth performance post-germination, conduct more detailed photophysiology experiments, and construct a preliminary transcriptome to identify targeted genes. This foundational research is expected to last approximately six months and involves collaboration between Newcastle University and the John Innes Centre. The findings will support further funding applications for extract purification, validation, and potential commercialisation routes.
Newcastle University is a comprehensive public research university in Newcastle upon Tyne, with broad academic and translational activity. Its city‑centre Newcastle Helix innovation district—developed with Newcastle City Council and Legal & General—co‑locates researchers with companies and hosts national innovation centres to enable fast collaboration. Deep integration with Newcastle upon Tyne Hospitals NHS Foundation Trust, supported by a joint research office, enables streamlined study setup, access to clinical populations, and end‑to‑end clinical translation. Research is backed by competitive funding from UKRI councils, the National Institute for Health and Care Research, major charities, the European Union, and industry. A dedicated technology transfer office supports IP, licensing, spinouts, and knowledge‑transfer partnerships.